Image unavailable in extracted textREGULATIONS UNDER THE NATIONAL HEALTH ACT 1953.*
I, THE GOVERNOR-GENERAL in and over the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Regulations under the National Health Act 1953.
Dated this twelfth
day of May , 1954.
Stamp J. Northcott
Deputy of the Governor-General.
By His Excellency’s Command,
Stamp Earle Page
Minister of State for Health.
Image unavailable in extracted textNational Health (Pharmaceutical Benefits) Regulations.
Citation.
These Regulations may be cited as the National Health (Pharmaceutical Benefits) Regulations.
Interpretation.
2.—(1.) In these Regulations, unless the contrary intention appears—
“authorized form” means a form authorized by the Director-General;
“authorized prescription form” means a paper, not less than five or more than six inches in length and not less than three or more than four inches in breadth, on which appear the name and address of a medical practitioner and at the top of which are written the letters “N.H.S.” and, in the case of a prescription written for a pensioner pharmaceutical benefit, the words “Pensioner Benefit”;
“entitlement card” means an entitlement card issued by the Commonwealth to a pensioner for the purposes of Part IV. and Part VII. of the Act;
“pensioner pharmaceutical benefit” means a pensioner pharmaceutical benefit under paragraph (b) of sub-section (1.) of section 85 of the Act as affected by regulations 9, 10 and 11 of these Regulations;
“pension number”, in relation to a pensioner, means his pension number appearing on his entitlement card;
Image unavailable in extracted text“the Act” means the National Health Act 1953;
* Notified in the Commonwealth Gazette on , 1954.
1441.—Price 10/5.5.1954.
“the Australian Pharmaceutical Formulary” means the latest edition for the time being of the hook called the Australian and New Zealand Pharmaceutical Formulary published by the Australian and New Zealand Pharmaceutical Association, or, if that edition has been added to or amended, that edition as affected by those additions or amendments;
“the British Pharmaceutical Codex” means the latest edition for the time being of the book called the British Pharmaceutical Codex published by direction of the Council of the Pharmaceutical Society of Great Britain, or, if that edition has been added to or amended, that edition as affected by those additions or amendments;
“the British Pharmacopoeia (1948)” means the edition of the book called the British Pharmacopoeia published under the direction of the General Medical Council of the United Kingdom in the year 1948 as affected by the additions or amendments contained in the 1951 Addendum to that book;
“the United States Pharmacopoeia” means the latest edition for the time being of the book called the Pharmacopoeia of the United States of America prepared by the Committee of Revision and published by authority of the United States Pharmacopoeia Convention, or, if that edition has been added to or amended, that edition as affected by those additions or amendments;
“trading hours”, in relation to an approved pharmaceutical chemist, means his trading hours established by or under the law of the State or Territory in which his premises are situated.
(2.) For the purposes of these Regulations—
(a) the abbreviations appearing in the columns headed “Strength” and “Form of Unit” in the First and Second Schedules have the following meanings:—
“amp.” means ampoule;
“cc.” means cubic centimetres;
“fl. oz.” means fluid ounces of 480 minims;
“G.” means grammes;
“γ” means microgrammes;
“gr.” means grains;
“hypo, tab.” means hypodermic tablet;
“I.M.” means intramuscular;
“I.U.” means international units determined in the year 1950 by the Expert Committee on Biological Standardisation of the World Health Organisation;
“I.V.” means intravenous;
“mg.” means milligrammes;
“M.” means millions of organisms;
“mil.” means millilitres;
“min.” means minims;
“U.” means units;
“U.S.P.” means the United States Pharmacopoeia; and
(b) the letters appearing in the column headed “Brand” in the First and Second Schedules denote the manufacturer whose name is specified in relation to those letters in the following table:—
(3.) In these Regulations, unless the contrary intention appears, a reference to prescribing or to the writing of a prescription shall be read as a reference to the writing of a prescription for the supply of a pharmaceutical benefit under Part VII. of the Act.
(4.) A disease or purpose specified in the column headed “Disease or Purpose” in the Second Schedule applies in relation to each form of the drug or medicinal preparation in relation to which that disease or purpose is specified.
(5.) Unless the contrary intention appears, weights and measures howsoever represented or expressed in these Regulations shall be deemed to relate to the table of weights and measures known as the “Apothecaries’ Table of Weights and Measures” that appears in the twelfth revision of the United States Pharmacopoeia.
(6.) In these Regulations, a reference to a Schedule by number shall be read as a reference to the Schedule to these Regulations so numbered, and a reference to a Form by letter shall be read as a reference to the Form so lettered in the Sixth Schedule.
(7.) Strict compliance with the Forms contained in the Sixth Schedule is not necessary and substantial compliance is sufficient.
Delegation.
3.—(1.) The Director-General may, in relation to a matter or class of matters, or to a State or part of the Commonwealth, by writing under his hand, delegate any of his powers and functions under these Regulations (except this power of delegation) to a Deputy Director of Health or to an officer of the Commonwealth Department of Health who is a pharmacist.
(2.) A power or function so delegated may be exercised or performed by the delegate with respect to the matter or class of matters, or with respect to the State or part of the Commonwealth, specified in the instrument of delegation.
(3.) A delegation under this regulation is revocable at will and does not prevent the exercise of a power or the performance of a function by the Director-General.
Persons not entitled to receive pharmaceutical benefits.
A person who is a passenger or a member of the crew on a foreign-going ship as defined by the Navigation Act 1912-1953 is not entitled to receive a pharmaceutical benefit.
Application for approval by a pharmaceutical chemist or hospital authority.
The Director-General may refuse to entertain an application by a pharmaceutical chemist or a hospital authority for approval under Part VII. of the Act unless the application for approval
is on and in accordance with Form A, Form B or Form C, whichever is appropriate, or in such form as the Director-General specially permits.
Signs to be displayed by pharmaceutical chemists.
6.—(1.) An approved pharmaceutical chemist shall display a sign in accordance with Form D in a conspicuous place in or on each of the premises in respect of which he is approved in such a manner as to he readily visible to persons who enter those premises.
(2.) The last preceding sub-regulation does not apply to or in relation to a friendly society dispensary the approval of which is limited in accordance with sub-section (3.) of section 91 of the Act.
Penalty: Ten pounds.
Certain requirements to be met after cancellation, &c., of approval.
Where the approval of an approved pharmaceutical chemist is suspended, revoked or cancelled, the approved pharmaceutical chemist—
(a) shall, if the Director-General so requests, deliver up to the Director-General all documents and forms supplied to him by the Commonwealth with respect to the provision of pharmaceutical benefits other than documents or forms that he has parted with in accordance with Part VII. of the Act and these Regulations or the Regulations repealed by that Part; and
(b) shall not display a sign indicating that he has been, or is, approved to supply pharmaceutical benefits.
Penalty: Fifty pounds.
General pharmaceutical benefits.
8.—(1.) The drugs and medicinal preparations that may be prescribed for supply, supplied and received as general pharmaceutical benefits are those specified in the First and Second Schedules.
(2.) Except as provided by the next succeeding sub-regulation, the general pharmaceutical benefits specified in the Second Schedule may be prescribed by a medical practitioner for the purposes of Part VII. of the Act only for the treatment of a disease or for a purpose specified in that Schedule in relation to the general pharmaceutical benefit.
(3.) A medical practitioner may, in respect of a pensioner, prescribe the following drugs for the treatment of any disease from which the pensioner is suffering:—
Quinine Bisulphate.
Quinine Dihydrochloride.
Quinine Hydrochloride.
Quinine Sulphate.
(4.) Water for Injection as prescribed in the First Schedule is not a general pharmaceutical benefit unless it is prescribed for supply in conjunction with and for administration with—
(a) Injection of Penicillin as prescribed as a general pharmaceutical benefit;
(b) Injection of Procaine Penicillin (Crystalline) as prescribed as a general pharmaceutical benefit;
(c) Dihydrostreptomycin as prescribed as a general pharmaceutical benefit;
(d) Streptomycin as prescribed as a general pharmaceutical benefit; or
(e) another drug or medicinal preparation that is prescribed as a general pharmaceutical benefit in the form of a hypodermic tablet.
Exceptions to pensioner benefits in British Pharmacopoeia.
9.—(1.) The following drugs and medicinal preparations, being drugs and medicinal preparations that are the subject of monographs in the British Pharmacopoeia, are not pensioner pharmaceutical benefits:—
(a) drugs and medicinal preparations that are medicinal gases;
(b) drugs and medicinal preparations containing diamorphine hydrochloride;
(c) drugs and medicinal preparations that are prescribed as general pharmaceutical benefits by the last preceding regulation.
(2.) A drug or medicinal preparation specified in the following list is not a pensioner pharmaceutical benefit unless it is an ingredient in, a medicinal compound that contains another drug or medicinal preparation that is a pensioner pharmaceutical benefit:—
Aether Anaestheticus.
Aether Vinylicus.
Aethylis Chloridum.
Alcohol.
Alcohol Tribromoethylicum.
Amyleni Hydras.
Bromethol.
Chloroformum.
Cyclopropanum.
Spiritus Methylatus Industrialis.
Thiopentonum Sodium.
Trichloroaethvlenum.
Benefits available to pensioners.
A drug or medicinal preparation specified in the Third Schedule is a drug or medicinal preparation available to pensioners if the drug or medicinal preparation—
(a) is in the form of a cachet, capsule, cream, eye ointment, extract, glycerine, injection, linament, liquor, mixture, ointment, pill, suppository, syrup or tablet indicated in that Schedule in the name or formula of that drug or medicinal preparation; or
(b) is an ingredient in a medicinal compound that contains another drug or medicinal preparation that is a pensioner pharmaceutical benefit.
Forms of pensioner pharmaceutical benefits.
A drug or medicinal preparation prescribed for supply in the form of a cachet, capsule, pill or tablet is not a pensioner pharmaceutical benefit unless the form in which it is prescribed for supply is a form specified in relation to that drug or medicinal preparation in the Third Schedule or in a monograph in the British Pharmacopoeia.
Maximum quantity or number of units of pharmaceutical benefits.
12.—(1.) The maximum quantity or number of units of a general pharmaceutical benefit that may be prescribed for supply at any one time is the quantity or number of units specified in the First or the Second Schedule, as the case may be.
(2.) The maximum quantity or number of units of a pensioner pharmaceutical benefit that may be prescribed for supply at any one time is, in respect of a form specified in the Fourth Schedule, such quantity or number of units as is specified in relation to that form in that Schedule.
Pharmaceutical benefits that may be supplied under section 93.
13.—(1.) The pharmaceutical benefits that a medical practitioner is authorized to supply for the purpose of section 93 of the Act are the general pharmaceutical benefits the names or formulae of which are specified in the Fifth Schedule and, subject to these Regulations, he may obtain those pharmaceutical benefits in the forms and quantities specified in that Schedule.
(2.) Where more than one form of a unit is specified in the Fifth Schedule, the maximum quantity or number of units of each of the forms so specified may be obtained by a medical practitioner under this regulation.
(3.) Where in the First Schedule more than one strength is specified in relation to a form of a drug or medicinal preparation that is specified in the Fifth Schedule, a medical practitioner may, for the purpose of section 93 of the Act, obtain that form of the drug or medicinal preparation in all or any of those strengths if the quantity or number of units of each strength obtained by the medical practitioner is the quantity or number of units contained in a standard package.
(4.) The last preceding sub-regulation does not entitle a medical practitioner to obtain a total quantity or number of units of more than one strength of a particular form of a drug or medicinal preparation that exceeds the maximum quantity or number of units specified in relation to that form in the Fifth Schedule.
(5.) In this regulation “standard package” means a package containing such quantity or number of units as the Director-General determines in relation to a specified product of a specified manufacturer.
Medical practitioners excepted from the authorization conferred by section 93.
A medical practitioner who is an approved medical practitioner and a medical practitioner who is practising his profession on a ship are not authorized to supply pharmaceutical benefits under section 93 of the Act.
Obtaining of drugs by medical practitioners for purpose of section 93.
15.—(1.) A medical practitioner shall not obtain a drug or medicinal preparation for the purpose of section 93 of the Act by any means other than by signing and lodging with an approved pharmaceutical chemist an order, in duplicate, on and in accordance with the authorized form.
(2.) A medical practitioner is not entitled to obtain a pharmaceutical benefit for the purpose of section 93 of the Act more often than once in any one month.
(3.) Where a medical practitioner has obtained a pharmaceutical benefit in accordance with this regulation, he is not entitled to obtain any further supply of that pharmaceutical benefit while he has in his possession a quantity or number of units of that pharmaceutical benefit equal to or greater than the maximum quantity or number of units allowable under regulation 13 of these Regulations.
Supply of pharmaceutical benefits by chemists for purpose of section 93.
An approved pharmaceutical chemist shall not supply a pharmaceutical benefit on an order given under the last preceding regulation unless the medical practitioner whose signature appears on the order is known to him or, if the medical practitioner is not known to him, he obtains from the person who presents the order particulars of the full name, address and medical registration number of the medical practitioner and endorses those particulars on the back of the order form.
Penalty: Twenty pounds.
Supply of particular brand for purpose of section 93.
Where a medical practitioner specifies in an order given under regulation 15 of these Regulations a particular brand of a pharmaceutical benefit specified in the Fifth Schedule, an approved pharmaceutical chemist shall supply that brand of the pharmaceutical benefit.
Penalty: Fifty pounds.
Payment for pharmaceutical benefits supplied for the purpose of section 93.
An approved pharmaceutical chemist who has supplied a pharmaceutical benefit to a medical practitioner for the purpose of section 93 of the Act in accordance with these Regulations is entitled to payment from the Commonwealth in respect of the supply of that pharmaceutical benefit at such rate and subject to such conditions as are determined by the Minister and applicable at the time of the supply.
Writing of prescriptions.
19.—(1.) A prescription is not duly written unless the medical practitioner who writes the prescription—
(a) writes the prescription in his own handwriting, unless the Director-General otherwise allows, on an authorized prescription form;
(b) writes the prescription in duplicate and marks that duplicate with the word “Duplicate”;
(c) dates and signs the prescription;
(d) states the name and address of the person for whom the pharmaceutical benefit is to be supplied;
(e) where the prescription is for the supply of a general pharmaceutical benefit—identifies that benefit by its name as specified in the First or the Second Schedule or by the trade name of a manufacturer an abbreviation of whose name appears in the column headed “Brand” in that Schedule;
(f) where the prescription is for the supply of a pensioner pharmaceutical benefit—
(i) states the pension number of the pensioner to whom the pensioner pharmaceutical benefit is to be supplied; and
(ii) if the benefit to be supplied consists of a single drug, indicates the mode in which the benefit is to be used; and
(g) where the prescription is for the supply of a general pharmaceutical benefit specified in the Second Schedule—endorses the prescription in his own handwriting with the words “Restricted Drug”.
(2.) A prescription is not duly written if the prescription—
(a) prescribes a general pharmaceutical benefit and a pensioner pharmaceutical benefit;
(b) includes two prescriptions for the same pharmaceutical benefit;
(c) prescribes pharmaceutical benefits for more than one person;
(d) prescribes more than two general pharmaceutical benefits or more than two pensioner pharmaceutical benefits;
(e) prescribes a pensioner pharmaceutical benefit by reference to a brand or in any other manner that indicates a brand; or
(f) prescribes for the supply to a person of a pharmaceutical benefit for the supply of which to the same person another prescription has been written by the same medical practitioner on the same day.
(3.) For the purposes of paragraph (d) of the last preceding sub-regulation, a prescription for the supply as a general pharmaceutical benefit of two or more strengths of a form of one of the following drugs or medicinal preparations shall be deemed to prescribe one general pharmaceutical benefit:—
Oily Injection of Aurothioglucose.
Injection of Calcium Aurothiomalate.
Pertussis Vaccine (Phase 1).
Aqueous Injection of Sodium Aurothiomalate.
Oily Injection of Sodium Aurothiomalate.
(4.) A prescription for Cortisone Acetate shall be deemed not to be duly written—
(a) unless the medical practitioner who writes the prescription has applied to the Director-General in accordance with Form E for authority to write such a prescription and that authority has been given on a form issued and numbered by the Director-General; or
(b) if he writes another prescription on the same authorized prescription form as that on which he prescribes Cortisone Acetate.
Repeat prescriptions.
20.—(1.) Subject to these Regulations, a medical practitioner may, in a prescription, direct that the supply of a pharmaceutical benefit be repeated a specified number of times not exceeding—
(a) in the case of a general pharmaceutical benefit—the number specified in the First or the Second Schedule in relation to that benefit; or
(b) in the case of a pensioner pharmaceutical benefit—such number as is determined by the Director-General in respect of the pensioner pharmaceutical benefit in the form specified in the prescription.
(2.) The last preceding sub-regulation does not entitle a medical practitioner to direct a repeat unless—
(a) in the case of a general pharmaceutical benefit—the quantity or number of units that he directs to be supplied on the first occasion is the maximum quantity or number of units specified in relation to that benefit in the First or the Second Schedule; or
(b) in the case of a pensioner pharmaceutical benefit in respect of which a maximum quantity or number of units is specified in the Fourth Schedule—the quantity or number of units that he directs to be supplied on the first occasion is that maximum.
Prescription of dangerous drugs.
21.—(1.) A prescription for the supply of a dangerous drug as a pharmaceutical benefit is not duly written if the medical practitioner who writes the prescription writes a prescription for another pharmaceutical benefit on the same authorized prescription form as that on which he prescribes the dangerous drug and he directs that one of those pharmaceutical benefits is to be supplied more than once.
(2.) In this regulation, “dangerous drug” means a drug or medicinal preparation in respect of which the law of the State or Territory in which the prescription is written provides that a pharmaceutical chemist who dispenses that drug or medicinal preparation or who dispenses it on the last of a number of occasions of supply indicated in a prescription for its supply, shall take possession of the prescription and cancel it or deliver it to the authority administering that law.
Recovery of cost of pharmaceutical benefits prescribed in excessive quantities.
If a Committee of Inquiry established under Division 2 of Part VIII. of the Act reports that, in its opinion, a medical practitioner has prescribed a quantity or number of units of a pharmaceutical benefit that is greater than the quantity or number of units of that pharmaceutical benefit that could reasonably be necessary for the proper medical treatment of the person in respect of whose medical treatment the prescription was written, the medical practitioner is liable to repay to the Commonwealth the amount of the cost to the Commonwealth of the excess quantity or number of units of the pharmaceutical benefit supplied on the prescription and that amount is recoverable as a debt due to the Commonwealth.
Supply of pharmaceutical benefits on prescriptions.
23.—(1.) An approved pharmaceutical chemist, an approved medical practitioner or an approved hospital authority (being the proprietor of a private hospital) is not authorized to supply a drug or medicinal preparation as a pharmaceutical benefit unless—
(a) subject to the next succeeding regulation, the prescription for its supply is surrendered to him;
(b) the prescription for its supply is duly written in accordance with these Regulations and is accompanied by a duplicate of the prescription on an authorized prescription form;
(c) where the prescription is for the supply of a pensioner pharmaceutical benefit—the entitlement card issued to the pensioner to whom the pensioner pharmaceutical benefit is to be supplied is produced; and
(d) the prescription for its supply is dated within six months before the date of its presentation.
(2.) An approved pharmaceutical chemist, an approved hospital authority or an approved medical practitioner is not authorized to supply Cortisone Acetate as a pharmaceutical benefit unless the prescription for its supply is accompanied by a numbered authority given under sub-regulation (4.) of regulation 19 of these Regulations.
Supply of pharmaceutical benefit before surrender of written prescription.
24.—(1.) A pharmaceutical benefit may be supplied by an approved pharmaceutical chemist or an approved hospital authority before the prescription for that pharmaceutical benefit is surrendered to him where, in a case of urgency, a medical practitioner, by oral or other means, communicates the prescription to the approved pharmaceutical chemist or approved hospital authority.
(2.) A medical practitioner who has communicated a prescription in the manner referred to in the last preceding sub-regulation shall reduce the communicated prescription to writing in accordance with regulation 19 of these Regulations and within twenty-four hours of the communication despatch the prescription so written to the approved pharmaceutical chemist or approved hospital authority who supplied the pharmaceutical benefit.
Penalty: Ten pounds.
(3.) This regulation does not apply to the following pharmaceutical benefits:—
Cortisone Acetate.
A pharmaceutical benefit that is a drug or medicinal preparation the prescription for which is required to be in writing by or under a law of the State or Territory of the Commonwealth in which the premises of the approved pharmaceutical chemist or approved hospital authority are situated.
(4.) In this regulation, “approved hospital authority” means a proprietor of a private hospital who is an approved hospital authority.
Supply of pharmaceutical benefit on first presentation of prescription.
An approved pharmaceutical chemist, approved medical practitioner or approved hospital authority (being the proprietor of a private hospital) is not authorized to supply a pharmaceutical benefit on the first presentation of a prescription unless—
(a) he writes on the back of the authorized prescription form and on the back of the duplicate his name and the number of his approval (if any) under the Act;
(b) if two pharmaceutical benefits have been prescribed on the authorized prescription form—he marks on that form and on the duplicate the first-written pharmaceutical benefit with the letter “A” and the other pharmaceutical benefit with the letter “B” and initials that marking; and
(c) in the case of an approved pharmaceutical chemist—he allots a serial number to the prescription and writes that serial number on the authorized prescription form and on the duplicate.
Supply of repeats.
26.—(1.) A pharmaceutical benefit shall not be supplied a number of times greater than the number specified, in accordance with regulation 20 or regulation 27 of these Regulations, in the prescription.
(2.) Where a prescription directs that a pharmaceutical benefit is to be supplied more than once, that benefit shall not be supplied (whether by the same supplier or by different suppliers) more than once on the same day.
Penalty: Ten pounds.
Special approval for repeats.
In special circumstances the Director-General may authorize, subject to such conditions as he determines, a pharmaceutical benefit to be prescribed by a medical practitioner and to be supplied a number of times greater than the number of times otherwise allowed by regulation 20 of these Regulations.
Repeat authorizations.
28.—(1.) An approved pharmaceutical chemist who supplies a pharmaceutical benefit on surrender of—
(a) a prescription that contains a direction to supply that benefit more than once; or
(b) a repeat authorization issued in accordance with this regulation,
shall, unless no further supply of the pharmaceutical benefit (after the supply that he is making) is authorized—
(c) issue, to the person presenting the prescription or repeat authorization, a repeat authorization, on and in accordance with an authorized form, in respect of each benefit the further supply of which is authorized;
(d) write the repeat authorization in duplicate and mark that duplicate with the word “Duplicate”;
(e) attach the repeat authorization to the duplicate of the prescription;
(f) in the case of the supply of a pharmaceutical benefit on the first occasion—mark on the repeat authorization the number of his approval under the Act and the serial number allotted by him to the prescription; or
(g) in the case of the supply of a pharmaceutical benefit on a subsequent occasion—mark on the repeat authorization that he issues the numbers marked, in pursuance of the last preceding sub-paragraph, on the repeat authorization presented to him.
(2.) A pharmaceutical benefit shall not be supplied upon surrender of the duplicate of a prescription unless—
(a) there is attached to that duplicate a repeat authorization—
(i) duly related to the duplicate prescription by a number or numbers;
(ii) where the prescription refers to two pharmaceutical benefits—referring to the first-written pharmaceutical benefit by the letter “A” and the second-written pharmaceutical benefit by the letter “B”; and
(iii) indicating that the pharmaceutical benefit to be supplied has not been supplied for the number of times directed in the prescription; and
(b) the person obtaining the pharmaceutical benefit surrenders the repeat authorization to the person supplying the pharmaceutical benefit.
(3.) An approved pharmaceutical chemist who supplies a benefit on presentation of a repeat authorization shall write his name on the back of the repeat authorization.
Penalty: Ten pounds.
Supply of brand of general pharmaceutical benefit specified in a prescription.
Where a prescription for the supply of a general pharmaceutical benefit, presented to an approved pharmaceutical chemist, approved hospital authority or approved medical practitioner, indicates a brand of that general pharmaceutical benefit, the approved pharmaceutical chemist, approved hospital authority or approved medical practitioner, as the case may be, shall not supply any other brand of that general pharmaceutical benefit unless the Director-General otherwise allows.
Penalty: Fifty pounds.
Receipts.
30.—(1.) Subject to this regulation, upon the supply to a person of a pharmaceutical benefit by an approved pharmaceutical chemist or an approved medical practitioner, that person shall sign and date a receipt for that pharmaceutical benefit and, if that person is not the person for whose treatment the prescription was written, that person shall write on the back of the authorized prescription form or repeat
authorization form, as the case may be, his address and a statement that he is obtaining the benefit for and on behalf of the person for whose treatment the prescription was written.
(2.) An approved pharmaceutical chemist or an approved medical practitioner shall not demand a receipt for the supply of a pharmaceutical benefit to a person unless the approved pharmaceutical chemist or approved medical practitioner has supplied that pharmaceutical benefit to that person.
(3.) Where a pharmaceutical benefit is supplied by an approved pharmaceutical chemist or an approved medical practitioner through the post or by rail or other means of transport and it is impracticable for him to obtain a receipt in accordance with the preceding provisions of this regulation, the approved pharmaceutical chemist or approved medical practitioner shall certify on the back of the authorized prescription form or repeat authorization form that he has supplied the pharmaceutical benefit, stating the date on which the supply was made and also particulars of the means by which the pharmaceutical benefit was supplied.
Penalty: Twenty pounds.
Presentation of prescriptions in trading hours.
31.—(1.) An approved pharmaceutical chemist shall, at all times, keep prominently displayed at each of the premises in respect of which he is approved, so as to be readily visible to persons who enter each premises, a notice in an authorized form setting out the trading hours during which services for the supply of pharmaceutical benefits are available.
(2.) Subject to the next succeeding regulation, a person is entitled on demand to be supplied with a pharmaceutical benefit from an approved pharmaceutical chemist only during trading hours.
Presentation of urgent prescriptions.
32.—(1.) A prescription for the supply of a pharmaceutical benefit marked “Urgent”, that marking being initialled by the medical practitioner writing the prescription, may be presented at any time to an approved pharmaceutical chemist at the premises in respect of which he is approved.
(2.) Subject to the next succeeding sub-regulation, where a prescription referred to in the last preceding sub-regulation is so presented, the approved pharmaceutical chemist shall, as soon as practicable, supply the pharmaceutical benefit.
Penalty: Ten pounds.
(3.) An approved pharmaceutical chemist may refuse to supply a pharmaceutical benefit outside trading hours unless a special charge is paid in accordance with the next succeeding regulation.
Special charges for supply outside trading hours.
33.—(1.) An approved pharmaceutical chemist is entitled to make a special charge of such amount as is determined by the Director General in respect of the supply of a pharmaceutical benefit outside trading hours.
(2.) Where two or more prescriptions are presented to an approved pharmaceutical chemist at the same time, being outside trading hours, for the supply of pharmaceutical benefits to the same person, the approved pharmaceutical chemist is entitled to make one special charge only.
Special charge for delivery.
When a pharmaceutical benefit is supplied by delivery at or to a place other than premises in respect of which the approved pharmaceutical chemist is approved, the premises at which an approved medical
practitioner carries on his practice or the hospital in respect of which an approved hospital authority is approved, as the case may he, the pharmaceutical chemist, medical practitioner or hospital authority is entitled to make a special charge equal to the cost of delivery and to refuse to deliver the pharmaceutical benefit unless the special charge is paid by or on behalf of the person to whom the pharmaceutical benefit is to he supplied.
Retention of prescriptions, &c.
Subject to regulation 21 of these Regulations, an approved pharmaceutical chemist, approved medical practitioner or approved hospital authority (being the proprietor of a private hospital) who or which supplies pharmaceutical benefits shall retain in his or its possession for a period of not less than twelve months from the respective dates on which prescriptions for the supply of the pharmaceutical benefits were written—
(a) in the case of prescriptions that do not bear instructions to supply pharmaceutical benefits more than once—the duplicates of those prescriptions;
(b) in the case of prescriptions that bear instructions to supply pharmaceutical benefits more than once—the duplicates of repeat authorizations issued in accordance with regulation 28 of these Regulations;
(c) where the pharmaceutical benefits are supplied on the last occasion on which supply is authorized—the duplicates of the prescriptions in respect of which repeat authorizations were issued; and
(d) the duplicates of order forms lodged under regulation 15 of these Regulations.
Penalty: Fifty pounds.
Proper stocks to be kept.
An approved pharmaceutical chemist shall, as far as practicable, keep in stock an adequate supply of all drugs and medicinal preparations that he may reasonably be expected to be called upon to supply as pharmaceutical benefits or as ingredients of pharmaceutical benefits.
Penalty: Ten pounds.
Forms suspected forged, &c.
Where an approved pharmaceutical chemist suspects that a prescription has not been signed by a medical practitioner or has been forged or fraudulently obtained, he is entitled, before supplying the pharmaceutical benefit specified in the prescription, to require that there be furnished to him a statement in accordance with an authorized form.
Standards of composition and purity of pharmaceutical benefits.
38.—(1.) The standards of composition and purity of drugs and medicinal preparations that may be supplied as pharmaceutical benefits or may be ingredients of pharmaceutical benefits are as prescribed by this regulation.
(2.) A drug or medicinal preparation that is a general pharmaceutical benefit specified in the First or the Second Schedule shall conform to such standards of composition and purity as are specified in relation to that drug or medicinal preparation in the British Pharmacopoeia, the British Pharmaceutical Codex or the Australian Pharmaceutical Formulary, as the case may be.
(3.) A drug or medicinal preparation that is a pensioner pharmaceutical benefit referred to in sub-paragraph (i) of paragraph (b) of sub-section (1.) of section 85 of the Act shall conform to the standards
of composition and purity constituted by the statements in the monograph in the British Pharmacopoeia relating to that drug or medicinal preparation.
(4.) A drug or medicinal preparation that is a pensioner pharmaceutical benefit specified in the Third Schedule shall—
(a) where the letters “A.P.F.” appear after the name or formula of the drug or medicinal preparation—conform to the standards of composition and purity constituted by the description of that drug or medicinal preparation in the Australian Pharmaceutical Formulary;
(b) where the letters “B.P.C.” appear after the name or formula of the drug or medicinal preparation—conform to the standards of composition and purity constituted by the statements in the monograph relating to that drug or medicinal preparation in the British Pharmaceutical Codex; and
(c) where no letters appear after the name or formula of the drug or medicinal preparation—conform to the standards of composition and purity constituted by the statements in the monograph relating to that drug or medicinal preparation in the British Pharmacopoeia (1948).
Samples.
When a sample of a drug, medicine or substance that may be supplied as, or may be an ingredient of, a pharmaceutical benefit is taken in pursuance of the power conferred upon an authorized person by section 104 of the Act and that sample conforms to the standards of composition and purity prescribed by the last preceding regulation, payment shall be made by the Commonwealth as if the quantity of the drug, medicine or substance taken as a sample had been supplied as a pharmaceutical benefit.
Entitlement cards.
For the purposes of paragraph (e) of sub-section (1.) of section 104 of the Act and paragraph (c) of sub-regulation (1.) of regulation 23 of these Regulations, an authorized person may, in his own name or in a fictitious name, present an entitlement card purporting to have been issued to a pensioner.
Surrender of forms.
41.—(1.) The Director-General may, by notice in writing served on a person, require that person to surrender to the Director-General or to a person specified in the notice, within a time specified in the notice, any unused forms that have been supplied to that person by or on behalf of the Commonwealth under or for the purposes of the Act or these Regulations and that are in the possession of the person.
(2.) A person upon whom a notice given in pursuance of the last preceding sub-regulation is served shall comply with that notice.
Penalty: Ten pounds.
Use of old forms.
Where the Commonwealth supplies or has supplied a form that is substantially in accordance with a form prescribed by these Regulations or an authorized form, except that it bears a reference or references to the Pharmaceutical Benefits Act 1947-1949, that form may be used for the purposes of these Regulations as if it were in accordance with the prescribed form or the authorized form, as the case may be, to which it substantially corresponds, and these Regulations apply in relation to that form as if it were in accordance with that prescribed form or that authorized form.
THE SCHEDULES.
Image unavailable in extracted textFIRST SCHEDULE. Reg. 8.
Image unavailable in extracted textDrugs and Medicinal Preparations that may be Prescribed for Supply, Supplied and Received as General Pharmaceutical Benefits.
Item Number.
Name or Formula
Strength.
Form of Unit.
Brand.
Maximum Quantity or Number of Units.
Number of Repeats.
1
Acetarsol Soluble, Injection of
.......................
2 cc. amp................
MB ...................
10
1
.......................
3 cc. amp................
MB ....................
10
1
2
Adrenalin Hydrochloride,
1 in 1,000 ................
0.5 cc. amp...............
DH, PD ................
6
1
Solution of
1 in 1,000 ................
1 cc. amp................
DH, KL, PD .............
6
1
1 in 1,000 ................
10 cc. vial...............
FA, PD .................
1
1
1 in 1,000 ................
1 fl. oz. bottle .............
DH, RT ................
1
..
1 in 1,000................
1 fl. oz. vial ..............
DH, FA, KL, PD, RT ........
1
..
1 in 100 .................
6 cc. vial ................
PD ....................
1
1
1 in 100 .................
10 cc. vial ...............
DH, FA.................
1
3
Adrenalin in Oil, Injection of
2 mg. per cc...............
1 cc. amp................
AH, DH, PD .............
6
1
4
Adrenalin Tartrate, Solution of
1 in 1,000 ................
1 cc, amp................
AH, BL, BW, DH
6
1
1 in 1,000 ................
10 cc. amp...............
BW ...................
1
1
1 in 1,000 ................
25 cc. bottle ..............
BW ....................
1
..
1 in 1,000 ................
30 cc. vial ...............
BT ....................
1
..
1 in 1,000 ................
1 fl. oz. bottle ..............
AH ...................
1
..
1 in 100 .................
7 cc. vial ................
BW ...................
1
1
5
Aloxidone ................
0.3 G...................
capsule .................
BS .....................
100
1
Image unavailable in extracted textImage unavailable in extracted text
First Schedule—continued.
Item Number.
Name or Formula.
Strength.
Form of Unit.
Brand.
Maximum Quantity or Number of Units.
Number of Repeats.
6
Amidone ................
5 mg. per cc...............
2 cc. amp................
BA ...................
6
..
5 mg. per cc...............
10 cc. vial ...............
BA ...................
1
..
10 mg. per cc..............
1 cc. amp................
BW, CM ...............
6
..
10 mg. per cc..............
10 cc. vial ...............
CM ...................
1
..
10 mg. per cc..............
20 cc. vial ...............
BA ...................
1
..
2.5 mg..................
tablet ...................
BA ...................
25
..
5 mg...................
tablet ...................
BA, BW, CM, ST ..........
25
..
7.5 mg..................
tablet ...................
BA ...................
25
..
10 mg...................
tablet ...................
BA ...................
25
..
7
Amyl Nitrite ..............
2 min...................
capsule .................
DH ...................
12
1
3 min...................
capsule .................
AH, DH ................
12
1
4 min...................
capsule ..................
AH, DH ................
12
1
5 min...................
capsule .................
AH, DH ................
12
1
8
Anahaemin ...............
.......................
2 cc. amp................
BD ...................
12
1
9
Anahepol ................
.......................
2 cc. amp................
AH ...................
12
1
10
Antazoline, Injection of .......
0.1 G. per 2 cc..............
2 cc. amp. ...............
BT, CB ................
10
..
11
Atropine Sulphate ..........
1/150 gr. per cc............
1 cc. amp. ...............
AH, BL, DH, KL..........
6
1
1/100 gr. per cc............
1 cc. amp................
AH, BL, BT, DH, KL.......
6
1
1/100 gr. per cc............
10 cc. vial ...............
FA ...................
1
..
1/50 gr. per cc.............
1 cc. amp................
BL, DH, KL .............
6
1
1/200 gr .................
hypo. tab. ................
BW, HY, PD .............
20
1
1/150 gr .................
hypo. tab................
BT, BW, DH, FA, HY, PD....
20
1
1/100 gr .................
hypo. tab................
BT, BW, DH, FA, HY, PD....
20
1
Image unavailable in extracted textImage unavailable in extracted text
First Schedule—continued.
Item Number.
Name or Formula.
Strength.
Form of Unit.
Brand.
Maximum Quantity or Number of Units.
Number of Repeats.
12
Aurothiglucose, Oily
0.01 G. .................
amp...................
SC ....................
1
3
Injection of
0.025 G.................
amp...................
SC ....................
1
3
0.05 G. .................
amp. ..................
SC ....................
6
..
0.1 G. .................
amp. ..................
SC ....................
6
..
0.01 G. per cc. ............
10 cc. vial ...............
SC ....................
1
..
0.1 G. per cc. .............
10 cc. vial ...............
SC ....................
1
..
13
Benzhexol Hydrochloride
2 mg. ..................
tablet ..................
LE, ST .................
100
1
5 mg. ..................
tablet ..................
LE ....................
100
1
14
Bismuth, Aqueous Injection of
......................
5 cc. amp................
BT ...................
2
..
......................
10 cc. amp. ..............
BT ...................
1
..
......................
25 cc. bottle .............
BW, MB................
1
..
......................
1 fl. oz. bottle .............
BT ...................
1
..
15
Bismuth Oxychloride, Aqueous
......................
1 cc. amp................
BD, BT ................
12
..
Injection of
......................
2 cc. amp. ...............
BD ...................
12
..
......................
3 cc. amp................
BD ...................
12
..
......................
25 cc. bottle .............
BW ...................
1
..
......................
30 cc. bottle .............
BD, EV ................
1
..
16
Bismuth Oxychloride, Oily
......................
2 cc. amp. ...............
DH ...................
12
..
Injection of
......................
3 cc. amp. ...............
DH ...................
12
..
17
Bismuth Salicylate, Oily
......................
1 cc. amp. ...............
AH, DH, KL .............
12
..
Injection of
......................
10 cc. amp. ..............
DH, KL ................
6
..
......................
25 cc. bottle
EV, KL ................
1
..
......................
50 cc. bottle
MB ...................
1
..
......................
60 cc. bottle .............
DH, KL ................
1
..
......................
2 fl. oz. bottle ............
PD ...................
1
..
Image unavailable in extracted textImage unavailable in extracted text
First Schedule—continued.
Item Number.
Name or Formula.
Strength.
Form of Unit.
Brand.
Maximum Quantity or Number of Units.
Number of Repeats.
18
Calcium Aurothiomalate,
10 mg...................
amp. ..................
CK ...................
1
3
Injection of
25 mg...................
amp. ..................
CK ...................
1
3
50 mg...................
amp...................
CK ...................
6
..
100 mg.................
amp...................
CK ...................
6
..
19
Calf Lymph................
......................
capillary tube .............
CS ....................
1
..
20
Camoquin Hydrochloride.......
0.2 G. ..................
tablet ..................
PD ....................
25
..
21
Campolon.................
......................
2 cc. amp................
BA ...................
5
1
......................
5 cc. amp................
BA ...................
6
1
......................
10 cc. vial ...............
BA ...................
1
1
22
Campolon Forte..............
......................
1 cc. amp................
BA ...................
6
1
......................
5 cc. vial ................
BA ...................
1
1
......................
10 cc. vial ...............
BA ...................
1
1
23
Carbachol..................
0.25 mg. per cc............
1 cc. amp................
AH, SY ................
6
..
2 mg. ..................
tablet ..................
BD, HY, MB, SY ..........
25
3
24
Carbarsone.................
0.25 G. .................
capsule .................
LY ...................
20
1
0.25 G. .................
tablet ..................
BW, HY, MB ............
20
1
25
Casydrol..................
2½% .. .................
500 cc. bottle .............
FC ....................
1
..
5% ....................
500 cc. bottle .............
FC ....................
1
..
26
Chiniofon..................
0.25 G..................
pill ...................
BA ...................
25
1
0.25 G. .................
tablet ..................
HY, IC .................
25
1
0.5 G .. .................
tablet ..................
IC ....................
25
1
27
Chloroquine................
0.2 G .. .................
tablet ..................
MB ...................
100
1
250 mg..................
tablet ..................
AN, BA ................
100
1
Image unavailable in extracted textImage unavailable in extracted text
First Schedule—continued.
Item Number.
Name or Formula.
Strength.
Form of Unit.
Brand.
Maximum Quantity or Number of Units.
Number of Repeats.
28
Cholera Vaccine ...........
4,000 M. per cc............
1 cc. amp................
CS ....................
3
..
4,000 M. per cc. ...........
10 cc. vial ...............
CS ....................
1
..
8,000 M. per cc. ...........
1 cc. amp. ...............
CS ....................
2
..
8,000 M. per cc. ...........
10 cc. vial ...............
CS ....................
1
..
29
Dapsone ................
50 mg. .................
tablet ..................
AN ...................
100
..
100 mg. ................
tablet ..................
IC ....................
100
..
30
Darrow’s Solution .........
......................
1 litre bottle ..............
DH ...................
2
1
31
Dextrose, Aqueous Injection of
5% ...................
1 litre bottle ..............
DH ...................
6
1
10% ...................
1 litre bottle ..............
DH ...................
2
1
20% ...................
1 litre bottle ..............
DH ...................
2
1
25% ...................
1 litre bottle ..............
DH ...................
2
1
50% ...................
25 cc. amp...............
DH ...................
6
1
50% ...................
50 cc. amp...............
DH, PD ................
6
1
32
Dextrose in 1/5 Normal Saline for Injection
4% ...................
1 litre bottle ..............
DH ...................
6
1
33
Dextrose in Ringer’s Solution
5% ...................
1 litre bottle ..............
DH ...................
6
1
for Injection
10% ...................
1 litre bottle ..............
DH ...................
3
1
34
Diasone ................
0.33 G. .................
tablet ..................
PD ....................
200
1
35
Dicoumarol ..............
100 mg. ................
amp. ..................
OR ....................
3
..
50 mg..................
capsule .. ...............
AB, LY ................
50
1
100 mg. ................
capsule .. ...............
AB, LY ................
50
1
50 mg. .................
tablet ..................
OR ...................
50
1
Image unavailable in extracted textImage unavailable in extracted text
First Schedule—continued.
Item Number.
Name or Formula.
Strength.
Form of Unit.
Brand.
Maximum Quantity or Number of Units.
Number of Repeats.
36
Diethazine Hydrochloride
0.05 G..................
tablet ..................
MB ...................
100
1
0.25 G..................
tablet ..................
MB ...................
100
1
37
Diethylcarbamazine
50 mg..................
tablet ..................
BD, BW, LB .............
20
1
38
Digifortis
1/2 gr ..................
tablet ..................
PD ....................
50
1
1 gr. ...................
tablet ..................
PD ....................
50
1
39
Digitalis ................
1/2 gr ..................
tablet ..................
BW, DH, FA, HY, RT, SI......
100
1
1 gr. ...................
tablet ..................
BW, DH, FA, HY, RT, SI......
100
1
40
Digitoxin ...............
1/100 gr.................
hypo. tab. ...............
BW ....................
20
1
0.1 mg. .................
tablet ..................
BW, CM, KL, NA, SI, ST, WY.
100
1
0.2 mg..................
tablet ...................
CM, LY, ST, WY .. ..........
100
1
0.25 mg.................
tablet ..................
KL ...................
100
1
41
Digoxin ..................
0.5 mg. per cc. ............
1 cc. amp. ...............
BW ...................
12
1
0.5 mg. per cc. ............
30 cc. bottle ..............
BW ...................
1
1
0.25 mg.................
tablet ..................
BW ...................
100
1
42
Dihydroergotamine, injection of
1 mg. per cc..............
1 cc. amp. ...............
SZ .. .....................
6
..
43
Dihydromorphinone ........
......................
1.1 cc. amp. ..............
KN ...................
4
..
1/32 gr..................
hypo. tab. ................
KN ...................
20
..
1/20 gr .................
hypo. tab. ...............
KN ...................
20
..
1/25 gr .................
tablet ..................
KN ...................
20
..
Image unavailable in extracted text
Image unavailable in extracted textFirst Schedule—continued.
Item Number.
Name or Formula.
Strength.
Form of Unit.
Brand.
Maximum Quantity or Number of Units.
Number of Repeats.
44
Diiodohydroxyquinoline ..
0.21 G..................
tablet ..................
SY ....................
100
1
0.3 G. ..................
tablet ..................
MB ...................
100
1
45
Dimercaprol, Injection of ..
......................
2 cc. amp................
BT ....................
12
..
46
Diphenhydramine Hydro-chloride, Injection of
10 mg. per cc. ............
10 cc. vial ...............
PD ....................
1
1
47
Diphtheria and tetanus Toxoids
......................
1 cc. amp................
CS ....................
3
..
Combined
......................
5 cc. amp................
CS ....................
1
..
48
Diphtheria Antitoxin ..
1,000 U. ................
amp. ..................
CS ....................
2
1
2,000 U. ................
amp. ..................
BW, CS ................
2
1
4,000 U. ................
amp. ..................
BW, CS ................
2
1
6,000 U. ................
amp. .. .................
CS ....................
2
1
8,000 U.................
amp. ..................
BW, CS ................
2
1
10,000 U. ...............
amp. ..................
BW, CS ................
2
1
20,000 U. ...............
amp. ..................
BW, CS ................
2
1
49
Diphtheria Pertussis Antigen
......................
1 cc. amp................
CS, GL .................
3
..
......................
5 cc. amp................
CS ....................
1
..
......................
5 cc. vial ................
GL ...................
1
..
......................
7.5 cc. vial ..............
PD ....................
1
..
......................
10 cc. vial ...............
GL ...................
1
..
50
Diphtheria, Pertussis and..
......................
1 cc. amp. ...............
BW, CS, GL ..............
3
..
Tetanus Antigen
......................
5 cc. amp. ...............
CS ....................
1
..
......................
7.5 cc. vial ..............
PD, SD .................
1
..
......................
10 cc. vial ...............
BW, GL ................
1
..
Image unavailable in extracted textImage unavailable in extracted text
First Schedule—continued.
Image unavailable in extracted textImage unavailable in extracted text
First Schedule—continued.
Item Number.
Name or Formula.
Strength.
Form of Unit.
Brand.
Maximum Quantity or Number of Units.
Number of Repeats.
111
Neo-Hepatex .............
......................
2 cc. amp................
EV ...................
12
1
......................
10 cc. bottle ..............
EV ...................
1
1
......................
25 cc. bottle ..............
EV ...................
1
1
112
Neostigmine Bromide .......
15 mg. .................
tablet ..................
RO ...................
100
1
113
Neostigmine Methyl-sulphate,
0.5 mg. per cc. ............
1 cc. amp................
RO ...................
6
3
Injection of
2.5 mg. per cc.............
5 cc. vial ................
RO ...................
1
1
114
Nikethamide, Injection of.....
......................
1.7 cc. amp. ..............
CB ...................
5
..
......................
2 cc. amp................
AH, BD, BT, FM ..........
6
..
......................
5 cc. amp................
BD, BW ................
3
..
......................
5.5 cc. amp...............
CB ...................
3
..
115
Nucleotides, Injection of......
......................
10 co. amp...............
AH, EV, MJ .............
12
..
116
Ouabain, Injection of ........
0.25 mg. ................
amp...................
NA ...................
3
..
0.5 mg. .................
amp. ..................
NA ...................
3
..
117
Oxophenarsine Hydrochloride,
0.04 G..................
amp. ..................
PD ....................
2
1
Injection of
0.06 G .................
amp. ..................
PD ....................
2
1
118
Oxytocin, Injection of
......................
0.5 cc. amp. ..............
PD ....................
6
..
......................
1 cc. amp................
PD ....................
6
..
119
Pamaquin ...............
0.01 G. .................
tablet ..................
BA ...................
45
..
0.018 G.................
tablet ..................
IC ....................
45
..
0.036 G.................
tablet ..................
IC ....................
45
..
Image unavailable in extracted textImage unavailable in extracted text
First Schedule—continued.
Item Number.
Name or Formula.
Strength.
Form of Unit.
Brand.
Maximum Quantity or Number of Units.
Number of Repeats.
120
Papaveretum .............
1/6 gr. per cc.............
1 cc. amp................
BL ....................
6
..
1/3 gr. per cc.............
1 cc. amp................
BL, DH, RO .............
6
..
1/3 gr ..................
hypo. tab................
RO ...................
25
..
1/6 gr..................
tablet ..................
DH, RO ................
20
..
121
Papaverine Hydrochloride
1/3 gr. per cc.............
1 cc. amp................
KL ...................
6
..
1½ gr. per 5 cc. ...........
5 cc. amp. ...............
AN ...................
6
..
2 gr. per 10 cc.............
10 cc. amp. ..............
DH, HA, KL.............
6
..
3/4 gr ..................
tablet ..................
AN, KL, RT .............
25
1
1½ gr ..................
tablet ..................
AN, DH, FA, HA, KL, RT.....
25
1
122
Paramethadione ...........
0.3 G..................
capsule .................
AB ...................
100
2
123
Parenamine .. ..
......................
1,000 cc. bottle ...........
ST ....................
1
..
124
Penethamate Hydriodide .....
100,000 U...............
vial ...................
GL ...................
6
..
500,000 U...............
vial ...................
GL .....................
3
..
125
Penicillin, Injection of.......
5,000 U. ................
amp. ..................
CS ....................
6
..
15,000 U................
amp...................
CS ....................
6
..
100,000 U...............
amp. ..................
AH, BD, BT, CS, EV, GL, IC, SI
6
..
200,000 U................
amp. ..................
AH, BD, BT, BW, CS, EV, GL, IC, SI
6
..
500,000 U...............
amp...................
AH, BD, BT, CS, EV, GL, IC, SI
3
..
1,000,000 U..............
amp....................
AH, BD, BT, CS, EV, GL, IC, SI
1
..
Image unavailable in extracted textImage unavailable in extracted text
First Schedule—continued.
Item Number.
Name or Formula.
Strength.
Form of Unit.
Brand.
Maximum Quantity or Number of Units.
Number of Repeats.
126
Penicillin, Procaine, Aqueous
400,000 U...............
vial ...................
FA ....................
3
..
Suspension of
600,000 U...............
vial ...................
BT .. ..................
2
..
900,000 U...............
vial ...................
CS, DH. SI ..............
2
..
1,000,000 U..............
vial ...................
FA ....................
1
..
1,500,000 U..............
vial ...................
CS, SI .................
1
..
127
Penicillin’, Procaine (Crystalline),
300,000 U...............
amp. ..................
AH, BD, BT, BW, CS, DH, EV, IC, MB, SI
3
..
Injection of
400,000 U...............
amp....................
AH, BD, BT, BW, CS, EV, GL, IC, MB, SI
3
..
500,000 U...............
amp....................
CS ....................
3
..
600,000 U.................
amp...................
DH ...................
2
..
667,000 U...............
amp...................
CS ....................
2
..
900,000 U...............
amp...................
AH, BD, BT, BW, CS, EV, IC, MB, SI
2
..
1,200,000 U..............
amp...................
AH, BD, BT, BW, CS, DH, EV, IC, MB, SI
1
..
1,500,000 U..............
amp. ..................
CS, SI .................
1
..
128
Penicillin, Procaine, Oily
300,000 U. per cc..........
1 cc. amp................
CS, DH, FA, SI ...........
3
..
Injection of
600,000 U. ..............
amp...................
BT, DH, FA .............
2
..
1,000,000 U..............
amp. ..................
DH ...................
1
..
Pernaemon Crudum.........
......................
2 cc. amp..................
OR ...................
12
1
......................
10 cc. vial ...............
OR.....................
1
1
130
Pernaemon Fort ...........
......................
1 cc. amp. ...............
OR ...................
12
1
......................
5 cc. vial ................
OR ...................
1
1
Image unavailable in extracted textImage unavailable in extracted text
First Schedule—continued.
Item Number.
Name or Formula.
Strength.
Form of Unit.
Brand.
Maximum Quantity or Number of Units.
Number of Repeats.
131
Pernexin ................
......................
2 cc. amp................
SC ....................
6
1
132
Pertussis Vaccine (Phase 1)
1,000 M. per cc. ...........
1 cc. amp................
CS ....................
3
1
5,000 M. per cc. ...........
1 cc. amp................
CS ....................
3
1
5,000 M. per cc............
10 cc. vial ...............
CS ....................
1
..
10,000 M. per cc. ..........
1 cc. amp................
CS ....................
3
1
10,000 M. per cc...........
10 cc. vial ...............
CS ....................
1
..
20.000 M. per cc...........
1 cc. amp. ...............
GL ...................
3
1
20,000 M. per cc...........
5 cc. vial ................
GL .....................
1
..
20,000 M. per cc...........
10 cc. vial ...............
GL ...................
1
..
60,000 M. per 1.5 cc........
1.5 cc. vial ..............
PD ....................
1
..
50,000 M. per set ..........
set of 3 amps.............
SC ....................
1
..
133
Pethidine Hydrochloride .....
50 mg. per cc.............
1 cc. amp................
AH, BL, BT, BW, DH, FM, IC, KL, RO
6
..
50 mg. per cc.............
2 cc. amp. ...............
AH, BA, BL, BT, BW, CM, DH, FM, IC, KL, RO
6
..
50 mg. per cc.............
10 cc. vial ...............
CM ...................
1
..
50 mg. per cc. ............
25 cc. bottle..............
IC ....................
1
..
50 mg. per cc.............
50 cc. bottle ..............
RO ...................
1
..
25 mg. .................
tablet ..................
BT, BW, CM, DH, IC, KL, RO, SI
25
..
50 mg..................
tablet ..................
BA, BT, BW, CM, DH, FM, IC, KL, RO, SI
25
..
134
Pethidine Scopolamine ......
Pethidine Hydrochloride 100 mg. per amp.
2 cc. amp. ...............
BW, KL, RO .............
6
..
Scopolamine 0.43 mg. per amp..
......................
......................
Image unavailable in extracted textImage unavailable in extracted text
First Schedule—continued.
Item Number.
Name or Formula.
Strength.
Form of Unit.
Brand.
Maximum Quantity or Number of Units.
Number of Repeats.
135
Phemitone ...............
1/2 gr ..................
tablet ..................
AS, BA, BT, FA, IC, SI ......
100
1
1 gr ...................
tablet ..................
AS, BA, IC, SI ...........
100
1
3 gr ...................
tablet ..................
AS, BA, BT, FA, IC, SI ......
100
1
136
Phenadoxone Hydrochloride
10 mg. per cc.............
1 cc. amp................
GL ...................
6
..
10 mg. .................
tablet ..................
GL ...................
25
..
137
Phenobarbitone Sodium, Injection of
1½ gr. per cc.............
1 cc. amp. ...............
BT ....................
6
..
3 gr. per cc.................
1 cc. amp................
BL, DH, PM, MB ..........
6
..
3 gr. per 1.5 cc............
1.5 cc. amp. ..............
EV ...................
6
..
3 gr. per 2 cc.............
2 cc. amp................
AH ...................
6
..
3.1 gr. per 5 cc............
5 cc. amp................
DH ...................
6
..
138
Phenylindanedione .........
50 mg. .................
tablet ..................
EV ...................
50
..
139
Phenytoin Sodium .........
0.03 G .................
capsule.................
PD ....................
100
1
0.1 G ..................
capsule .................
PD ....................
100
1
0.1 G. ..................
tablet ...................
BT, DH, FM .............
100
1
140
Phthalysulphacetamide ......
0.5 G ..................
tablet ..................
AN, BS, CM, SC ..........
100
..
141
Phthalylsulphathiazole .......
0.5 G ..................
tablet ..................
MB, SI .................
100
..
142
Physostigmine Sulphate ......
1/100 gr ................
hypo. tab. ...............
PD ....................
20
..
143
Picrotoxin, Injection of ......
3 mg...................
amp. ..................
AH ...................
6
..
5 mg. ..................
amp. ..................
AH, DH, MT .............
6
..
0.3% ..................
20 cc. bottle ..............
AB ...................
1
..
Image unavailable in extracted textImage unavailable in extracted text
First Schedule—continued.
Item Number.
Name or Formula.
Strength.
Form of Unit.
Brand.
Maximum Quantity or Number of Units.
Number of Repeats.
144
Pitressin Tannate in Oil, Injection of
......................
1 cc. amp..................
PD ....................
12
1
145
Pituitary (Posterior Lobe),
......................
0.5 cc. amp..............
BW, CS, PD .............
6
..
Injection of
......................
1 cc. amp................
BW, CS, PD .............
6
..
146
Primidone ...............
0.25 G. .................
tablet ..................
IC ....................
100
2
147
Procaine Hydrochloride in Normal Saline for Injection
0.1% ..................
1 litre bottle ..............
DH ...................
2
1
148
Procyclidine Hydrochloride
5 mg...................
tablet ..................
BW ...................
100
1
149
Proguanil Hydrochloride .....
0.1 G..................
tablet ..................
IC ....................
100
1
150
Promethazine Hydrochloride, Injection of
2.5% ..................
2 cc. amp. ...............
MB ...................
10
..
151
Protamine Sulphate...........
1% ...................
5 mil. amp...............
EV ...................
6
..
1% ...................
10 cc. amp. ..............
BT ....................
3
..
152
Protolex ................
......................
2 cc. amp. ...............
CM ...................
12
1
......................
10 cc. amp...............
CM ...................
1
1
153
Pyridoxine Hydrochloride,
50 mg. per cc.............
1 cc. amp. ...............
BL, CM, DH, FM, KL, PD, RO.
6
1
Injection of
50 mg. per 2 cc............
2 cc. amp................
BD, RO, VM .............
6
1
50 mg. per cc.............
5 cc. vial ................
LY ...................
1
1
50 mg. per cc. ............ ..
10 cc. vial...............
KL ...................
1
..
Image unavailable in extracted textImage unavailable in extracted text
First Schedule—continued.
Item Number
Name or Formula.
Strength.
Form of Unit.
Brand.
Maximum Quantity or Number of Units.
Number of Repeats.
154
quinidine Sulphate .........
3 gr ...................
tablet ..................
BW, DH ................
100
1
155
Reticulogen ..............
......................
0.5 cc. amp. ..............
LY ...................
6
1
......................
5 cc. amp. ...............
LY .....................
1
1
156
Ringer’s Solution For Injection
......................
1 litre bottle..............
DH ...................
4
1
157
Rondase ................
3 mg. ..................
amp...................
EV......................
6
1
158
Sodium Aurothiomalate,
0.001 G.................
amp. ..................
MB .....................
1
3
Aqueous Injection of
0.002 G.................
amp. ..................
MB ...................
1
3
0.005 G..................
amp...................
MB ...................
1
3
0.01 G..................
amp. ..................
MB ...................
1
3
0.02 G. .................
amp. ..................
MB ...................
1
3
0.05 G. .................
amp. ..................
MB ...................
6
1
0.1 G. ..................
amp. ..................
MB ...................
6
1
0.2 G ..................
amp. ..................
MB ....................
1
3
159
Sodium Aurothiomalate, Oily
0.01 G. .................
amp. ..................
MB .....................
1
3
Injection of
0.02 G. .................
amp. ..................
MB ...................
1
3
0.05 G. .................
amp...................
MB ...................
6
1
160
Sodium Chloride Hypertonic
3% ...................
1 litre bottle ..............
DH .....................
2
1
Solution for Injection
5% ...................
1 litre bottle ..............
DH ....................
2
1
Image unavailable in extracted textImage unavailable in extracted text
First Schedule—continued.
Item Number.
Name or Formula.
Strength.
Form of Unit.
Brand.
Maximum Quantity or Number of Units.
Number of Repeats.
161
Sodium Chloride Physiological
......................
2 cc. amp................
AH, BL, DH, KL ..........
6
1
Solution for Injection
......................
5 cc. amp................
AH, BL, BT, DH, KL .......
6
1
......................
10 cc. amp...............
AH, BL, BT, CS, DH, KL, PD..
6
1
......................
20 cc. amp...............
BL, DH ................
6
1
......................
50 cc. amp...............
DH ...................
3
1
......................
1 litre bottle ..............
DH ...................
2
1
162
Sodium Chloride Physiological
5% Dextrose .............
1 litre bottle ..............
DH ...................
2
1
Solution (with Dextrose) for
10% Dextrose ............
1 litre bottle ..............
DH ...................
2
1
Injection
20% Dextrose ............
1 litre bottle ..............
DH ...................
2
1
25% Dextrose ............
1 litre bottle ..............
DH .....................
2
1
163
Sodium Sulphate Solution for Injection
4.28% .................
1 litre bottle ..............
DH ....................
2
1
164
Solapsone ...............
7½ gr ..................
tablet ..................
BW ...................
200
..
165
Succinylsulphathiazole ......
0.5 G ..................
tablet ..................
AN, MB, SD .............
100
..
166
Sulphacetamide ...........
0.5 G ..................
tablet ...................
AN, BS, BT, DH, FA, FM, SC, SI
50
..
167
Sulphadiazine ............
0.3 G ..................
tablet .. ..................
AB, KL, PD, TO ............
50
..
0.5 G ..................
tablet ..................
AB, AN, BT, BW, CM, DH, FA, FM, HY, KL, MB, MR, PD, RT, SC, SI
50
..
168
Sulphadimidine .. ..........
0.25 G. .................
tablet ..................
IC ....................
50
..
0.5 G. ..................
tablet ..................
AN, IC ...................
50
..
Image unavailable in extracted textImage unavailable in extracted text
First Schedule—continued.
Item Number.
Name or Formula.
Strength.
Form of Unit.
Brand.
Maximum Quantity or Number of Units.
Number of Repeats.
169
Sulphafurazole ............
0.5 G. ..................
tablet ..................
RO ...................
50
..
170
Sulphaguanidine ...........
0.5 G ..................
tablet ..................
AB, AN, BT, BW, CM, DH, FM, HY, IC, KL, NS, RT, SI
100
..
171
Sulphamerazine ...........
0.5 G ..................
tablet ..................
AB, AN, BW, DH, FA, FM, HY, KL, RT, SI
50
..
172
Sulphamethizole ...........
0.1 G. ...................
tablet ..................
WW ...................
30
..
173
Sulphapyridine .. ............
0.5 G ..................
tablet ..................
MB .....................
50
..
174
Sulpharsphenamine, Injection of
0.10 G. .................
amp...................
BT ....................
2
1
0.15 G. ...................
amp. ..................
BT, EV .................
2
1
0.3 G. ..................
amp...................
BT, EV ..................
2
1
0.45 G. .................
amp...................
BT, EV .................
2
1
0.6 G. ..................
amp...................
BT, EV .................
2
1
0.75 G. .................
amp. ..................
BT ......................
2
1
0.9 G...................
amp...................
BT ....................
2
1
175
Sulphathiazole ............
0.3 G ..................
capsule .................
LY ...................
50
..
0.5 G ..................
tablet ..................
BT, BW, CB, FM, HY, KL, MB
50
..
176
Sulphonamides, Mixed, (A)—Two
0.25 G. .................
tablet ..................
DH ...................
50
..
Sulphonamides
0.3 G. ..................
tablet ..................
AB, HY, KL .............
50
..
0.5 G..................
tablet ..................
AB, DH, HY, KL, TO, VR....
50
..
Image unavailable in extracted textImage unavailable in extracted text
First Schedule—continued.
Item Number.
Name or Formula.
Strength.
Form of Unit.
Brand.
Maximum Quantity or Number of Units.
Number of Repeats.
177
Sulphonamides, Mixed, (B)—
0.25 G. .................
tablet ..................
CM, MB ................
50
..
Three Sulphonamides
0.3 G ..................
tablet ..................
AB, KL, TO .............
50
..
0.33 G. .................
tablet ....................
AN ...................
50
..
0.5 G. ..................
tablet ..................
AD, AN, CM, FA, FM, HY, KL, MB, SI, TO
50
..
178
Sulphonamides, Mixed, (C)— Four
0.3 G ..................
tablet ..................
KL ...................
50
..
Sulphonamides
0.5 G. ..................
tablet ..................
KL ...................
50
..
179
Suprarenal Cortex Extract,
200γ per cc..............
10 cc. bottle ..............
PD ....................
3
1
injection of
......................
10 cc. vial ...............
AH ...................
3
1
180
T.A.B. Vaccine (Antityphoid-
1 cc. containing—
1 cc. amp................
CS ....................
3
..
paratyphoid)
1,000 M. Typhosus.........
10 cc. vial .. ..
CS ....................
1
..
500 M. Para-typhosus A......
......................
......................
500 M. Para-typhosus B......
......................
......................
181
Tetanus Antitoxin ..........
500 I.U.................
amp. ..................
CS ....................
6
1
1,000 I.U................
amp...................
CS ....................
6
1
1,500 I.U................
amp....................
BW, CS ..................
6
1
5,000 I.U................
amp. ..................
CS....................
6
1
10,000 I.U. ..............
amp....................
BW, CS ................
6
1
182
Tetanus Toxoid (Formalinized)
......................
1 cc. amp................
CS ....................
3
..
183
Theophylline with Ethyl-
0.366 G. per 10 mil.........
10 mil. amp..............
AB ...................
6
..
Enediamine
0.732 G. per 2 mil..........
2 mil. amp. ..............
AB ...................
6
..
0.48 G. per 2 mil...........
2 mil. I.M. amp............
DH, HA ................
6
..
0.5 G. per mil.............
2 mil. I.M. amp............
AH, BW, CM ............
6
..
0.24 G. per 10 mil..........
10 mil. I.V. amp...........
DH, HA ................
6
..
Image unavailable in extracted textImage unavailable in extracted text
First Schedule—continued.
Item Number.
Name or Formula.
Strength.
Form of Unit.
Brand.
Maximum Quantity or Number of Units.
Number of Repeats.
183-
Theophylline with Ethyl-
0.25 G. per 10 mil ..........
10 mil. I.V. amp. ..........
AH, BW, CM .. ...........
6
..
contd.
enediamine—continued.
1½ gr ..................
tablet ..................
BT, BW, CM, DH, FA, HA, HY, KL, RT, SI, SM
100
1
2.34 gr. .................
tablet ..................
AB ...................
100
1
184
Thiacetazone .............
25 mg..................
tablet ..................
BT....................
100
..
50 mg. .................
tablet ..................
AH, AN, FM, HT ...........
50
..
185
Thiouracil, Methyl .........
0.05 G..................
tablet ..................
AN, BW ................
100
1
0.1 G. ..................
tablet ..................
AN, BD, BW, IC ..........
100
1
0.2 G. ..................
tablet ..................
AN, BD, BW, IC, MB .......
100
1
186
Thiouracil, Propyl ..........
25 mg. .................
tablet ..................
AN ...................
100
1
50 mg..................
tablet ..................
AN ...................
100
1
187
Thyroid B.P..............
1/32 gr .................
tablet ...................
BW, CS, DH .............
100
3
1/16 gr .................
tablet ..................
BW, CS, DH .............
100
3
1/10 gr .................
tablet ..................
BW, CS ................
100
3
1/8 gr ..................
tablet ..................
BW, CS, DH .............
100
3
1/4 gr ..................
tablet ..................
AS, BW, CS, DH, FA, GP, PD, SI
100
3
1/2 gr ..................
tablet ..................
AS, BW, CS, DH, FA, GP, PD, SI
100
3
1 gr. ...................
tablet ..................
AS, BW, CS, DH, FA, GP, PD, SI
100
3
1½ gr ..................
tablet ..................
BW, CS, DH, GP, SI ........
100
3
2 gr ...................
tablet ..................
BW, DH, FA, GP, PD, SI .....
100
3
2½ gr ..................
tablet ..................
BW, CS, DH, GP, SI ........
100
3
5 gr...................
tablet ..................
GP ....................
100
3
188
Tiger Snake Antivenene ......
1,500 U.................
amp...................
CS ....................
4
1
Image unavailable in extracted textImage unavailable in extracted text
First Schedule—continued.
Item Number.
Name or Formula.
Strength.
Form of Unit.
Brand.
Maximum Quantity or Number of Units.
Number of Repeats.
189
Triethanolamine Trinitrate
1 mg...................
tablet ..................
SC ....................
50
1
190
Troxidone ...............
0.3 G. ..................
capsule .................
AB ...................
100
1
0.15 G. .................
tablet ..................
AB ...................
100
1
191
Vasopressin, Injection of .....
......................
0.5 cc. amp................
CS, PD .................
6
..
......................
1 cc. amp. ...............
CS, PD .................
6
..
192
Vitamin K, Aqueous Injection of
2.5 mg. per p.5 cc..........
0.5 cc. amp...............
AB ...................
6
1
5 mg. per cc..............
1 cc. amp................
AB, BL, FM .............
6
1
10 mg. per cc.............
1 cc. amp. ................
BL, BT, DH, GL, KL, RO.....
6
1
75 mg. per cc...............
1 cc. amp................
BL, OR ................
6
1
193
Vitamin K, Oily Injection of
5 mg. per cc..............
1 cc. amp................
BD, BW, CK, VM..........
6
1
10 mg. per cc.............
1 cc. amp................
DH, KL ................
6
1
194
Vitamin K (Oral) ..........
1 mg. ..................
capsule .................
BA ...................
100
1
1 mg...................
tablet ..................
LY ...................
100
1
4 mg...................
capsule .................
PD ....................
100
1
4.8 mg. .................
tablet ..................
AB....................
100
1
5 mg...................
tablet ..................
BD, DH, FM, KL, RT, SI .....
100
1
10 mg..................
tablet ..................
BD, CK, CM, DH, GL, HY, KL, RO, RT, SI, VM
100
1
195
Water for Injection............
......................
2 cc. amp................
AH, BL, BT, DH, EV, KL.....
6
1
......................
5 cc. amp................
AH, BL, BT, DH, EV, KL.....
12
1
......................
10 cc. amp. ..............
AH, AN, BL, BT, CS, DH, EV, KL
12
1
196
Wydase ................
150 U. .................
amp. ..................
WY ...................
5
1
Image unavailable in extracted textSECOND SCHEDULE. Reg. 8.
Image unavailable in extracted textDrugs and Medicinal Preparations that may be Prescribed fob Supply, Supplied and Received as General Pharmaceutical Benefits only for the treatment of a disease or purpose.
Item Number.
Name or Formula.
Strength.
Form of Unit.
Brand.
Maximum Quantity or Number of Units.
Number of Repeats.
Disease or Purpose.
1
Aureomycin .............
50 mg...........
capsule .........
IE ............
25
..
Acute amoebic dysentery
100 mg. .........
capsule .........
LE ...........
25
..
Acute and sub-acute bacterial
250 mg..........
capsule .........
LE ...........
16
..
endocarditis-streptococcus fae-
100 mg..........
vial............
LE ...........
6
..
calis
Staphylococcal infections which do not respond to penicillin
Pneumonia which has not responded to penicillin nor to sulphonamides
Psittacosis
Urinary tract infections due to streptococcus faecalis
2
Calcium Para-aminosalicylate
1.5 G...........
cachet ..........
KL, WA .........
200
1
Tuberculosis
2.0 G. ...........
cachet ..........
WA ...........
200
1
5 gr ............
tablet ..........
WA ...........
200
1
7½ gr ...........
tablet ..........
KL, WA ........
200
1
...............
100 G. tin .......
WA ...........
1
1
...............
400 G. tin .......
WA ...........
1
1
3
Caramiphen Hydrochloride
0.05 G...........
tablet ..........
GE ...........
100
1
Parkinsonism
4
Chloramphenicol ..........
0.125 G. .........
capsule .........
PD ............
12
..
Typhoid fever
0.25 G...........
capsule .........
PD............
12
..
Brucellosis
Typhus and other rickettsial diseases
Influenzal meningitis
Granuloma inguinale
Image unavailable in extracted textImage unavailable in extracted text
Second Schedule—continued.
Staphylococcal infections that do not respond to either penicillin or aureomycin
Urinary tract infections due to gram negative bacilli that do not respond to sulphonamides
Meningitis due to bacterium coli if other forms of treatment are unsuccessful
5
Chloramphenicol Palmitate
0.125 G. per 4 cc.
60 cc. bottle
PD .............
1
..
Any disease or purpose specified in this column in relation to chloramphenicol
6
Cortisone Acetate ..........
25 mg..........
tablet .......
AN, BD, BT, DH, RL, SC
40
1
Acute rheumatic carditisAddison’s disease
25 mg. per cc.....
20 cc. vial ....
DH, SO ..........
1
..
Total adrenalectomy
50 mg. per cc.....
10 cc. vial ....
SC .............
1
..
7
Deoxycortone Acetate, Aqueous Injection of
5 mg...........
amp........
CB, SC ..........
4
..
Addison’s disease
50 mg..........
amp........
CB, SC ..........
1
..
Image unavailable in extracted textImage unavailable in extracted text
Second Schedule—continued.
Item Number
Name or Formula.
Strength.
Form of Unit.
Brand.
Maximum Quantity or Number of Units.
Number of Repeats.
Disease or Purpose.
8
Deoxycortone Acetate,
25 mg...........
amp.........
CB ..............
1
..
Addison’s disease
Aqueous Suspension of
50 mg...........
amp.........
CB ..............
1
..
9
Deoxycortone Acetate, Oily
2 mg. ...........
amp.........
OR ..............
4
..
Addison’s disease
Injection of
5 mg. ...........
amp.........
BD, CB, OR, SC .....
4
..
10 mg...........
amp.........
BD, CB, OR, SC .....
4
..
50 mg...........
implant.......
BD, OR ...........
1
..
100 mg............
implant.......
BD, CB, OR, SC .....
1
..
5 mg. per cc.......
5 cc. vial......
OR ..............
1
..
10 mg. per cc......
10 cc. vial.....
CB, OR...........
1
..
10
Dienoestrol ..............
5 mg. ............
tablet ........
AN, BD, DH, KL.....
100
1
Carcinoma of the prostate
10 mg...........
tablet ........
KL ..............
100
1
Mammary carcinoma
11
Dihydrostreptomycin ........
1 G.............
vial .........
AN, BD, DN, GL, SI, SP, ST
5
3
Any disease or purpose specified in this column in relation to streptomycin, but only if the person being treated for that disease or purpose is allergic to streptomycin
12
Folic Acid ...............
15 mg. per cc......
1 cc. amp......
AN, KL, LE ........
12
..
Sprue or the sprue-like syndrome
5 mg............
tablet ........
AN, CM, HY, KL, PD, SI
100
1
13
Isoniazid ................
50 mg. ..........
tablet ........
AN, DH, HA, HT, HY. KL, MB, NS, RO, SC, SI
100
1
Tuberculosis
100 mg. .........
tablet ........
MB, RO ...........
100
1
Image unavailable in extracted textImage unavailable in extracted text
Second Schedule—continued.
Item Number.
Name or Formula.
Strength.
Form of Unit.
Brand.
Maximum Quantity or Number of Units.
Number of Repeats.
Disease or Purpose.
14
Pancreatin ...............
5 gr.............
tablet ........
OP, PD ...........
100
..
Fibrocystic disease of the pancreas
15
Para-aminosalicylic Acid .....
0.3 G............
tablet ........
CO, DH, HY, KL SI...
200
1
Tuberculosis
0.5 G............
tablet ........
AN, DH, HA, HY, KL, SI
200
1
16
Phenindamine Tartrate.......
25 mg...........
tablet ........
RO..............
100
1
Parkinsonism
17
Progesterone, Injection of.....
5 mg. ...........
Amp........
BD, BT, CB, FM, KL, OR, SC
6
..
Threatened abortion
10 mg...........
amp. ........
BD, CB, FM, KL, OR, SC
6
..
20 mg...........
I. V. amp......
SC...............
3
..
18
Quinine Bisulphate.........
5 gr.............
tablet ........
BW, DH, FA, HY, PD
100
1
Malaria
19
Quinine Hydrochloride.......
3 gr. per cc........
1 cc. amp.....
DH..............
6
1
Malaria
6¼ gr. per cc.......
1 cc. amp.....
DH..............
6
1
9¼ gr. per 2 cc.....
2 cc. amp.....
DH..............
6
1
15½ gr. per 2 cc.....
2 cc. amp.....
DH..............
6
1
5 gr. ............
capsule ......
PD ..............
100
1
5 gr. ............
tablet ........
DH..............
100
1
20
Quinine Hydrochloride ......
5 gr.............
tablet ........
BW, DH ..........
100
1
Malaria
21
Quinine Sulphate ..........
5 gr.............
tablet ........
DH, HY, SI ........
100
1
Malaria
Image unavailable in extracted textImage unavailable in extracted text
Second Schedule—continued.
Item Number.
Name or Formula.
Strength.
Form or Unit.
Brand.
Maximum Quantity or Number of Units.
Number of Repeats.
Disease or Purpose.
22
Sodium Para-aminosalicylate
1.5 G...........
cachet ......
AN, BT, HT, KL, WA, WB
200
1
Tuberculosis
2.0 G..........
cachet......
WA ..............
200
1
0.5 G..........
capsule......
HA ..............
200
1
5 gr...........
tablet .......
CB, CM, DH, HY, KL, SI, WA
200
1
7½ gr ..........
tablet .......
AN, BT, CB, CM, DH, HA, HT, HY, KL, SI, WA
200
1
20% ...........
10 cc. vial....
AN, HT, KL, WA
6
..
23
Stilboestrol ..............
1 mg...........
amp........
AH, BD, DH ..
6
..
Carcinoma of the prostate
5 mg...........
amp........
AH, BD, BW, DH, KL
6
..
Mammary carcinoma
1 mg...........
Tablet......
AN, BD, BW, DH, FA, HA, HY, RT, SI
100
1
5 mg.............
tablet .......
AN, BD, BW, DH, FA, HA, HY, KL, RT, SI
100
1
10 mg..........
tablet .......
CM, KL ...........
100
1
24
Streptomycin .............
1 G ............
vial ........
AH, AN, BD, BW, DN, EV, GL, IC, MB, ST
5
3
Infections due to haemophilus influenza
Chancroid
Pneumonia due to bacillus Friedlander
Acute tuberculosis
Acute exacerbations in chronic tuberculosis
Salmonella infections
Image unavailable in extracted textImage unavailable in extracted text
Second Schedule—continued.
Item Number.
Name or Formula.
Strength.
Form of Unit.
Brand.
Maximum Quantity or Number of Units.
Number of Repeats.
Disease or Purpose.
24—contd.
Streptomycin—continued.
Bacillary dysentery not responding to sulphonamides
Surgical conditions of the bowel and of the thoracic organs
Tularaemia
Infections due to pseudomonas pyocyaneus
25
Terramycin.................
50 mg...........
capsule ......
PF ...............
25
..
Acute amoebic dysentery
100 mg..........
capsule ......
PF...............
25
..
Acute and sub-acute bacterial endocarditis—streptococcus faecalis
250 mg..........
capsule ......
PF...............
16
..
Staphylococcal infections which do not respond to penicillin
50 mg. ..........
tablet ........
PF...............
25
..
Pneumonia which has not responded to penicillin nor to sulphonamides
100 mg..........
tablet ........
PF ...............
25
..
Psittacosis
250 mg..........
tablet ........
PF...............
16
..
Urinary tract infections due to streptococcus faecalis
100 mg...........
vial.........
PF...............
6
..
250 mg. per 10 cc.
10 cc. vial ....
PF...............
6
..
26
Terramycin Oral Suspension
0.25 G. per 5 cc.
1 fl. oz. bottle...
PF...............
1
..
Any disease or purpose specified in this column in relation to terramycin
27
Testosterone................
100 mg...........
implant ......
BD, CB, OR, SC .....
1
..
Mammary carcinoma
150 mg..........
implant ......
OR ..............
1
..
Castration
200 mg..........
implant ......
OR...............
1
..
Image unavailable in extracted textImage unavailable in extracted text
Second Schedule—continued.
Item Number.
Name of Formula.
Strength.
Form of Unit.
Brand.
Maximum Quantity or Number of Units.
Number of Repeats.
Disease or Purpose.
28
Testosterone, Methyl ........
25 mg. ..........
tablet ........
AN, BD, BS, BT, CS, HY, KL, OR, SC
25
1
Mammary carcinoma Castration
50 mg...........
tablet ........
AN, BD, BS, BT, HY, KL, OR, SC
25
1
29
Testosterone Oenanthate, Injection of
250 mg. per cc. ....
1 cc. amp......
SC ..............
1
..
Mammary carcinoma Castration
30
Testosterone Phenyl Propionate, Injection of
50 mg. per cc.......
1 cc. amp.......
OR...............
3
..
Mammary carcinoma
50 mg. per cc.......
5 cc. vial ......
OR ..............
1
..
Castration
31
Testosterone Propionate, Injection of
25 mg. per cc.......
1 cc. amp.....
AH, AN, BD, BS, BT, BW, CB, FM, KL, OR, SC
12
..
Mammary carcinoma Castration
50 mg. per cc.......
1 cc. amp. ....
AH, BD, BS, CB, PM, OR, SC
12
..
50 mg. per cc.......
10 cc. vial ....
CB, KL, OR, SC .....
1
..
100 mg. per 2 mil....
2 mil. amp....
BD, PM, OR, SC .....
1
..
100 mg..........
implant ......
BD ..............
1
32
Tetracycline ................
50 mg...........
capsule ......
LE ..............
25
..
Any disease or purpose specified in this column in relation to aureomycin
100 mg...........
capsule ......
LE ..............
25
..
250 mg. ..........
capsule ......
LE ..............
16
..
50 mg...........
tablet ........
PF ...............
25
..
100 mg..........
tablet ........
PF ...............
25
..
250 mg..........
tablet ........
PF ...............
16
..
100 mg..........
vial.........
LE ..............
6
..
Image unavailable in extracted textImage unavailable in extracted text
Second Schedule—continued.
Item Number.
Name of Formula.
Strength.
Form of Unit.
Brand.
Maximum Quantity or Number of Units.
Number of Repeats.
Disease or Purpose.
33
Vitamin B12, Injection of ..
10γ per cc........
1 cc. amp. ....
BD, DH ...........
12
1
Established megalocytic anaemias
15γ per cc........
1 cc. amp.....
PD ..............
12
1
20γ per cc........
1 cc. amp.....
AH, AN, BD, BL, BT, BW, CK, CM, DH, EV, GL, IC, KL, NS, SI, ST, VM
12
1
50γ per cc. ........
1 cc. amp.....
AH, BD, BL, BT, BW, CK, DH, EV, GL, IC, NS, VM
6
1
100γ per cc........
1 cc. amp.....
AH, AN, BD, BL, BT, BW, CK, CM, EV, GL, IC, KL, PD, SI, VM
1
1
100γ per cc........
10 cc. vial.....
CM ..............
1
..
200γ per cc .......
1 cc. amp......
BT ...............
1
..
1,000γ per cc......
1 cc. amp......
AN, CM, GL ........
1
..
1,000γ per cc......
10 cc. vial.....
CM ..............
1
..
THIRD SCHEDULE.
Reg. 10.
Pensioner Benefits Additional to those Covered by Monograph in the British Pharmacopoeia.
Item No.
Name or Formula of Drug or Medicinal Preparation.
1
Acetonum B.P.C.
2
Acetum Scillae
3
Acid Hydrocyanicum Dilutum B.P.C.
4
Acid Sulphuricum Dilutum B.P.C.
5
Acidum Hypophosphorosum Dilutum
6
Acriflavina
7
Adeps
8
Adeps Benzoinatus
9
Aethylenum
10
Agar
11
Amidopyrina
12
Ammonii Bromidum B.P.C.
13
Aqua (Potable Water)
14
Aqua Anisi B.P.C.
15
Aqua Chlorbutolis A.P.F.
16
Argentoproteinum Mite B.P.C.
17
Balsamum Peruvianum
18
Betanaphthol
19
Caffeina Citrata B.P.C.
20
Caffeina et Sodii Benzoas
21
Calcii Mandelas
22
Cera Flava
23
Chiniofonum
24
Chromii Trioxidum
25
Codeina
26
Cremor Penicillini Sterilisatus
27
Dicoumarol
28
Ephedrinae Sulphas B.P.C.
29
Extractum Colchici Siccum
30
Extractum Colocynthidis Compositum
31
Extractum Ergotae Liquidum
32
Extractum Fellis Bovini
33
Extractum Glycyrrhizae
34
Extractum Hepatis Liquidum
35
Extractum Krameriae Siccum
36
Extractum Senegae Liquidum
37
Ferri Carbonas Saccharatus
38
Glycerinum Acidi Borici
39
Glycerinum Boracis
40
Hexoestrol
41
Hydrargyrum cum Creta
42
Infusum Aurantii
43
Infusum Aurantii Concentratum
44
Infusum Buchu B.P.C.
45
Infusum Calumbae
46
Infusum Calumbae Concentratum
47
Infusum Calumbae Recens
48
Infusum Caryophylli
49
Infusum Caryophylli Concentratum
50
Infusum Senegae
51
Infusum Senegae Concentratum
52
Infusum Sennae
53
Infusum Sennae Concentratum
54
Injectio Bismuthi Salicylatis
55
Injectio Caffeinae et Sodii Benzoatis
56
Injectio Oestradiolis Dipropionatis
57
Injectio Penicillini Oleosa
Third Schedule—continued.
Item No.
Name or Formula of Drug or Medicinal Preparation.
58
Injectio Physostigminae Salicylatis
59
Injectio Pituitarii Posterioris
60
Injectio Procainae et Adrenalinae Mitis
61
Injectio Sodii Citratis Anticoagulans
62
Injectio Sodii Citratis cum Dextroso
63
Injectio Strychninae Hydroehloridi
64
Injectio Sulphadiazinae Sodii
65
Iodoformum
66
Ipomoeae Resina
67
Laevulosum
68
Linimentum Aconiti
69
Linimentum Belladonnae
70
Liquor Ammoniae Aromaticus B.P.C.
71
Liquor Glycerylis Trinitratis B.P.C.
72
Liquor Magnesii Bicarbonatis
73
Magenta B.P.C.
74
Magnesii Phosphas B.P.C.
75
Mistura Aluminii Hydroxidi A.P.F.
76
Mel Depuratum
77
Mistura Sennae Composita
78
Oestradiolia Dipropionas
79
Oestronum
80
Oculentum Cocainae
81
Oculentum Physostigminae
82
Oleum Cajuputi
83
Oleum Cari
84
Oleum Citronellae B.P.C.
85
Oleum Cocois B.P.C.
86
Oleum Pini B.P.C.
87
Oxymel Scillae
88
Pelletierinae Tannas
89
Phenazonum
90
Pilula Aloes
91
Pilula Colocynthidis et Hyoscyami
92
Pilula Digitalis Co. B.P.C.
93
Pilula Ferri Carbonatis
94
Pilula Hydrargyri
95
Pilula Rhei Composita
96
Pilula Sodii Oleatis Co. A.P.F.
97
Pix Carbonis B.P.C.
98
Potassii Acetas
99
Potassii Chloras
100
Quininae et Aethylis Carbonas
101
Sapo Animalis
102
Sapo Durus
103
Sodii Carbonas Exsiccatus
104
Sodii Nitris
105
Sodii Phosphas Exsiccatus
106
Sodii Sulphas Exsiccatus
107
Spiritus Aetheris Nitrosi
108
Spiritus Cajuputi
109
Spiritus Camphorae
110
Strychnina B.P.C.
111
Sulphacetamidum
112
Sulphadiazina Sodium
113
Sulphonal
114
Suppositoria Acidi Tannici
115
Suppositoria Belladonnae
116
Suppositoria Bismuthi Subgallatis
117
Suppositoria Cocainae
118
Suppositoria Hamamelidis et Zinci Oxidi
Third Schedule—continued.
Item No.
Name or Formula of Drug or Medicinal Preparation.
119
Suppositoria Iodoformi
120
Suppositoria Morphinae
121
Suppositoria Phenolis
122
Syrupus Ferri Phosphatis Compositus
123
Syrupus Glucosi Liquidi
124
Syrupus Glyeerophosphatum Compositus A.P.F.
125
Syrupus Limonis Neutralis A.P.F.
126
Syrupus Pruni Serotinae
127
Syrupus Ruber A.P.F.
128
Syrupus Scillae
129
Tabellae Hexoestrolis
130
Tabellae Hydrargyri cum Creta
131
Tabellae Oestroni
132
Tabellae Phenazoni
133
Tabellae Potassii Chloratis
134
Tabellae Sodii Salicylatis
135
Tabellae Theobrominae Compositae B.P.C.
136
Tabellae Thiouracili
137
Theophyllina et Sodii Acetas
138
Talcum Purificatum B.P.C.
139
Thiouracilum
140
Tinctura Calumbae
141
Tinctura Capsici
142
Tinctura Catechu
143
Tinctura Cocci
144
Tinctura Gelsemii B.P.C.
145
Tinctura Lobeliae Aetherae
146
Tinctura Myrrhae
147
Tinctura Persionis A.P.F.
148
Tinctura Quassiae
149
Tinctura Scillae
150
Tinctura Senegae
151
Tinctura Strophanthi
152
Tinctura Tolutana
153
Tinctura Valerianae Ammoniata
154
Triethanolamina B.P.C.
155
Unguentum Capsici
156
Unguentum Gallae cum Opio B.P.C.
157
Unguentum Hydrargyri Compositum
158
Unguentum Hydrargyri Subchloridi
159
Unguentum Phenolis
160
Unguentum Zinci Oleatis
161
Unguentum Zinci Oxidi Aquosum
162
Xylenum B.P.C.
FOURTH SCHEDULE.
Reg. 12.
Maximum Quantities or Numbers of Units of Pensioner Pharmaceutical Benefits.
Image unavailable in extracted textSIXTH SCHEDULE.
Form A.
Reg. 5.
Commonwealth or Australia.
National Health Act 1953.
APPLICATION FOR APPROVAL AS A PHARMACEUTICAL CHEMIST.
(By a Registered Pharmaceutical Chemist.)
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse"><tbody><tr style="height:13pt"><td colspan="3" style="width:152pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="text-indent:4.5pt; text-align:justify; widows:2; orphans:2; font-size:11pt"><span>*I,</span></p></td><td colspan="5" style="width:324.65pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="text-align:justify; widows:2; orphans:2; font-size:11pt"><span>of </span><span style="width:226.59pt; display:inline-block"></span><span style="width:234pt; display:inline-block"></span><span>,</span></p></td></tr><tr><td colspan="3" style="width:152pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="text-indent:4.5pt; text-align:justify; widows:2; orphans:2; font-size:11pt"><span>We,</span></p></td><td colspan="5" style="width:324.65pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="text-align:justify; widows:2; orphans:2; font-size:11pt"><span></span></p></td></tr><tr><td colspan="3" style="width:152pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="text-align:justify; widows:2; orphans:2; font-size:11pt"><span>trading as</span><span style="width:39.68pt; display:inline-block"></span></p></td><td colspan="5" style="width:324.65pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="text-align:justify; widows:2; orphans:2; font-size:11pt"><span>, hereby apply for approval as a</span></p></td></tr><tr style="height:8.5pt"><td colspan="8" style="width:487.45pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="text-align:justify; widows:2; orphans:2; font-size:11pt"><span>pharmaceutical chemist under the </span><span style="font-style:italic">National Health Act </span><span>1953 in respect of premises situated at</span></p></td></tr><tr><td colspan="2" style="width:48.65pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="text-indent:4.5pt; text-align:justify; widows:2; orphans:2; font-size:11pt"><span>*I,</span></p></td><td rowspan="2" style="width:92.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:middle"><p style="font-size:11pt"><span>hereby declare that</span></p></td><td colspan="2" style="width:43.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="text-align:justify; widows:2; orphans:2; font-size:11pt"><span>*I am</span></p></td><td rowspan="2" style="width:97.2pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:middle"><p style="font-size:11pt"><span>are a pharmaceutical</span></p></td><td style="width:46.8pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="text-align:justify; font-size:11pt"><span>*chemist</span></p></td><td rowspan="2" style="width:104.95pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:middle"><p style="font-size:11pt"><span>registered as such</span></p></td></tr><tr><td colspan="2" style="width:48.65pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="text-indent:4.5pt; text-align:justify; widows:2; orphans:2; font-size:11pt"><span>We,</span></p></td><td colspan="2" style="width:43.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="text-align:justify; widows:2; orphans:2; font-size:11pt"><span>we are</span></p></td><td style="width:46.8pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="text-align:justify; widows:2; orphans:2; font-size:11pt"><span>*chemists</span></p></td></tr><tr><td colspan="3" style="width:152pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="text-align:justify; widows:2; orphans:2; font-size:11pt"><span>under the law of the *State of</span></p></td><td colspan="5" style="width:324.65pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="text-align:justify; widows:2; orphans:2; font-size:11pt"><span>*Territory.</span></p></td></tr><tr><td style="width:47.45pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="text-indent:4.5pt; text-align:justify; widows:2; orphans:2; font-size:11pt"><span>*I</span></p></td><td colspan="2" rowspan="2" style="width:93.75pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:middle"><p style="widows:2; orphans:2; font-size:11pt"><span>further declare that</span></p></td><td style="width:39.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="text-align:justify; widows:2; orphans:2; font-size:11pt"><span>*I am</span></p></td><td colspan="4" rowspan="2" style="width:274.55pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:middle"><p style="widows:2; orphans:2; font-size:11pt"><span>willing to supply on demand, at or from the</span></p></td></tr><tr><td style="width:47.45pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="text-indent:4.5pt; text-align:justify; widows:2; orphans:2; font-size:11pt"><span>We</span></p></td><td style="width:39.3pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="text-align:justify; widows:2; orphans:2; font-size:11pt"><span>we are</span></p></td></tr><tr><td colspan="8" style="width:487.45pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="text-align:justify; widows:2; orphans:2; font-size:11pt"><span>premises specified above, pharmaceutical benefits in accordance with Part VII of the </span><span style="font-style:italic">National</span></p></td></tr><tr><td colspan="8" style="width:487.45pt; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="margin-bottom:8pt; text-align:justify; widows:2; orphans:2; font-size:11pt"><span></span><span style="font-style:italic">Health Act </span><span>1953 and the Regulations made under that Act.</span></p></td></tr><tr style="height:0pt"><td style="width:58.25pt"></td><td style="width:1.2pt"></td><td style="width:103.35pt"></td><td style="width:50.1pt"></td><td style="width:4pt"></td><td style="width:108pt"></td><td style="width:57.6pt"></td><td style="width:115.75pt"></td></tr></tbody></table>
Dated this day of , 19
(Signature of Applicant).
To the Director-General of Health,
Commonwealth of Australia.
* Strike out whichever is inapplicable.
Fifth Schedule—continued.
Form B.
Reg. 5.
Commonwealth of Australia.
National Health Act 1953.
APPLICATION FOR APPROVAL AS A PHARMACEUTICAL CHEMIST.
(By a Friendly Society, &c.)
I, of
the person authorized to make this application by
, which is a Friendly Society or body carrying on business for the benefit of members of a friendly society or friendly societies, hereby apply for approval of that Friendly Society or body as a pharmaceutical chemist under the National Health Act 1953, in respect of premises situated at
The Friendly Society or body is prepared to supply on demand, at or from its premises specified above, pharmaceutical benefits in accordance with Part VII. of the National Health Act 1953 and the Regulations made under that Act.
*I declare that the Friendly Society or body was carrying on the business of a pharmaceutical chemist on the first day of August, 1945.
Dated this day of , 19 .
(Signature of person authorized to make application).
To the Director-General of Health,
Commonwealth of Australia.
* Strike out if inapplicable.
Image unavailable in extracted textForm C.
Reg. 5.
Commonwealth of Australia.
National Health Act 1953.
APPLICATION FOR APPROVAL AS A HOSPITAL AUTHORITY.
I, of ,
the person authorized to make this application by the *governing body / the proprietor of the
Hospital, which is a *private /public hospital,
hereby apply under the National Health Act 1953 for approval of that hospital authority for the purpose of supplying general pharmaceutical benefits to patients receiving treatment in or at that hospital.
The hospital authority is prepared to supply pharmaceutical benefits in accordance with Part VII. of the National Health Act 1953 and the Regulations made under that Act.
The dispensing of drugs and medicinal preparations at the hospital is performed by or under the direct supervision of. who
is a *medical practitioner./pharmaceutical chemist.
Dated this day of , 19 .
(Signature of person authorized to make application).
To the Director-General of Health,
Commonwealth of Australia.
* Strike out whichever is inapplicable.
Fifth Schedule—continued
Form D.
Reg. 6.
Image unavailable in extracted text
Department of Health.
APPROVED
PHARMACEUTICAL
CHEMIST.
National Health Act.
Image unavailable in extracted textForm E.
Reg. 19 (4.).
Commonwealth of Australia.
National Health Act 1953.
APPLICATION FOR AUTHORITY TO PRESCRIBE CORTISONE ACETATE.
(By a Medical Practitioner.)
I, of ,
hereby apply under sub-regulation (4.) of regulation 19 of the National Health. (Pharmaceutical Benefits) Regulations for authority to write a prescription for Cortisone Acetate as prescribed as a general pharmaceutical benefit in the Second Schedule to those Regulations in the following strength, form of unit, brand and quantity or number of units:—
I certify that the pharmaceutical benefit is required for the treatment of , who is suffering from , being a disease or purpose specified in that Schedule in relation to that pharmaceutical benefit, and that in my opinion there is no other drug available that would be equally effective in this case.
Dated this day of , 19 .
(Signature of Medical Practitioner).
To the Director-General of Health,
Commonwealth of Australia.
Image unavailable in extracted textBy Authority : L.F.Johnston, Commonwealth Government Printer, Canberra.